|
Real-time Estimate
Cboe BZX
12:56:12 2026-09-04 EDT
|
5-day change | 1st Jan Change | ||
| 101.03 USD | +0.40% |
|
+3.68% | +27.93% |
| 08-20 | Mirum Pharmaceuticals Insider Sold Shares Worth $4,000,000, According to a Recent SEC Filing | MT |
| 08-19 | US FDA approves Regeneron's rare bone disorder drug | RE |
| Market Cap | 6.53B 5.62B 5.29B 4.83B 9.04B 617B 9.06B 62.51B 24.26B 317B 24.54B 24B 1,020B | P/E 2026 * |
-6.65x | P/E 2027 * | -125x |
|---|---|---|---|---|---|
| Enterprise Value | 6.72B 5.78B 5.44B 4.97B 9.29B 634B 9.32B 64.24B 24.93B 325B 25.22B 24.67B 1,048B | EV / Sales 2026 * |
9.64x | EV / Sales 2027 * | 8.1x |
| Free-Float |
98.34% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MIRM | Delayed | |
CBOE
| MIRM | Real-time | |
|
Deutsche Boerse AG
| 08D | Delayed | |
|
Tradegate
| 08D | Real-time | |
|
Börse Stuttgart
| 08D | Delayed | |
|
Boerse Muenchen
| 08D | Real-time | |
|
Xetra
| 08D | Delayed |
Last Transcript : Mirum Pharmaceuticals, Inc.
| 1 day | +0.40% | ||
| 1 week | +3.68% | ||
| Current month | +3.06% | ||
| 1 month | -3.14% | ||
| 3 months | +9.26% | ||
| 6 months | +8.61% | ||
| Current year | +27.93% |
| 1 week | 95.6 |  | 101.99 |
| 1 month | 88.88 | | 107 |
| Current year | 73.82 | | 130 |
| 1 year | 63.23 | | 130 |
| 3 years | 23.14 | | 130 |
| 5 years | 12.82 | | 130 |
| 10 years | 6.51 | | 130 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 47 | 2019-03-20 | |
Eric Bjerkholt
DFI | Director of Finance/CFO | 66 | 2023-09-10 |
Peter Radovich
PSD | President | 48 | 2024-01-15 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Grey
CHM | Chairman | 73 | 2019-03-20 |
Patrick Heron
BRD | Director/Board Member | 55 | 2018-11-06 |
| Director/Board Member | 47 | 2018-10-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/18/26 | Exercice | Controller/Auditor | 120,000 | 0.1968% | ||
| 8/11/26 | Sell | Chief Financial Officer | -6,001 | 0.0098% | ||
| 8/10/26 | Exercice | Founder | 60,000 | 0.0984% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.40% | +3.68% | +36.22% | +265.86% | 6.53B | |
| -1.19% | -2.46% | +54.22% | +105.25% | 1,034B | |
| -0.88% | +3.13% | +54.63% | +72.03% | 671B | |
| -1.20% | +0.66% | +20.74% | +76.03% | 460B | |
| +0.14% | -0.47% | +29.49% | +38.56% | 353B | |
| -1.33% | +4.72% | +24.69% | +45.55% | 309B | |
| -1.15% | +0.30% | -1.49% | +12.31% | 255B | |
| -1.52% | +1.25% | +56.31% | +72.36% | 240B | |
| -0.88% | +1.15% | -17.09% | -54.39% | 207B | |
| -0.14% | +3.66% | +33.91% | +100.92% | 188B | |
| Average | -0.74% | +1.23% | +29.16% | +73.45% | 372.33B | |
| Weighted average by Cap. | -0.93% | +1.04% | +36.65% | +67.06% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 697M 599M 564M 515M 964M 65.77B 966M 6.66B 2.59B 33.74B 2.62B 2.56B 109B | 816M 702M 661M 603M 1.13B 77.04B 1.13B 7.81B 3.03B 39.53B 3.06B 3B 127B |
| Net income | -933M -803M -755M -690M -1.29B -88.09B -1.29B -8.93B -3.46B -45.2B -3.5B -3.43B -146B | -32.99M -28.39M -26.71M -24.4M -45.65M -3.11B -45.77M -316M -122M -1.6B -124M -121M -5.15B |
| Net Debt | 181M 156M 146M 134M 250M 17.08B 251M 1.73B 672M 8.76B 679M 665M 28.24B | 74.95M 64.5M 60.68M 55.43M 104M 7.08B 104M 717M 278M 3.63B 281M 275M 11.7B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-04 | US$101.05 | +0.42% | 104,340 |
| 26-09-03 | US$100.63 | +0.80% | 453,040 |
| 26-09-02 | US$99.83 | +1.52% | 495,626 |
| 26-09-01 | US$98.34 | +0.30% | 398,380 |
| 26-08-31 | US$98.05 | +0.61% | 419,812 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MIRM Stock
Select your edition
All financial news and data tailored to specific country editions
